Quarterly ResultApr 30, 2026, 11:34 AM
LLY Q1 Revenue +55.5% to $19.8B; EPS $8.26; Net Income +168%
AI Summary
Eli Lilly & Co (LLY) reported robust first-quarter 2026 results, with revenue surging 55.5% to $19.8 billion and net income increasing 168.1% to $7.4 billion. Diluted EPS rose 170% to $8.26. Growth was primarily driven by strong sales of Mounjaro and Zepbound. The company also completed the acquisition of Ventyx Biosciences for $1.1 billion and noted an unfavorable development in the Emgality patent litigation.
Key Highlights
- Q1 2026 Revenue: $19.8B, up 55.5% from $12.7B YoY.
- Q1 2026 Net Income: $7.4B, up 168.1% from $2.8B YoY.
- Q1 2026 Diluted EPS: $8.26, up 170% from $3.06 YoY.
- Mounjaro revenue reached $8.7B, up from $3.8B YoY.
- Zepbound revenue reached $4.2B, up from $2.3B YoY.
- Acquired Ventyx Biosciences for $1.1B in March 2026.
- Net cash provided by operating activities was $5.3B, up from $1.7B YoY.
- Emgality patent litigation reversed, leading to a recognized charge.
Price Impact
More from LLY